To help you understand what the U.S. is doing to address problems and challenges in the healthcare sector, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
Uncle Sam has made some progress in reducing cancer drug shortages by working with manufacturers to restart U.S. production facilities that were previously shut down, as well as securing vital overseas supplies.
One drug, cisplatin, often used to treat ovarian, bladder and testicular cancer has already returned to near 100% pre-shortage levels of supply. However, The U.S. still has an overall shortage of 15 cancer drugs, per the Food and Drug Administration (FDA), because of manufacturing and supply chain problems.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
In 2022, manufacturing site closures reduced the U.S. supply of cisplatin, (used to treat bladder cancer, testicular cancer, or ovarian cancer), carboplatin (used for ovarian cancer) and methotrexate (used for leukemia, breast and lung cancer, and more) by nearly half, leading to treatment delays for cancer patients.
One survey by the National Comprehensive Cancer Network in June found that 70% of its members were experiencing a cisplatin shortage, while virtually all their members found carboplatin difficult to come by. Around 20% of cancer patients rely on platinum-based chemotherapy drugs, such as cisplatin and carboplatin, for treatment, according to federal health statistics.
Several U.S. manufacturers have exited this market in recent years, increasing American reliance on foreign imports from China and India, in particular. It remains unclear how Uncle Sam will address this long-term problem, which may ultimately require using government demand to bolster manufacturing.
One bill now under consideration by Congress, the Drug Shortage Prevention Act, would require manufacturers to report anticipated shortages ahead of time.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
- Costs of 34 Medicare Drugs To Be Capped Until December
- Select Health Aims to Offer Lower Drug Prices Via New Partnership
- How to Save on Prescription Medication
-
Verizon's Latest Streaming Perk Bundles Netflix and Max for $10Verizon's myPlan customers will be able to take advantage of the Netflix-Max streaming bundle soon.
-
Stock Market Today: Stocks Slip to Start Jobs Week
Coming off a fifth straight weekly win, the main indexes took a breather ahead of a busy week of jobs data.
-
FDA Approves Zepbound, the Latest Weight-Loss Drug: The Kiplinger Letter
The Kiplinger Letter Eli Lily’s Zepbound will undercut its rivals’ pricing but still costs over $1,000 a month.
-
More Signs of Belt-Tightening and a Slowing Economy: The Kiplinger Letter
The Kiplinger Letter Although fewer banks are tightening lending standards, more businesses and households are feeling the squeeze.
-
The Recent Uptick In Global Trade Won’t Last: The Kiplinger Letter
The Kiplinger Letter Global trade continues to fall as economic growth around the world cools.
-
Consumers Have $1 Trillion More Savings Post-Pandemic: The Kiplinger Letter
The Kiplinger Letter GDP data show Americans have more savings than they did pre-pandemic.
-
Once-Booming Gun Sales Have Slumped: The Kiplinger Letter
The Kiplinger Letter Since 2022, FBI background checks, a close proxy for gun purchases, have slumped.
-
The Era of Super-Low Interest Rates Could Be Over: The Kiplinger Letter
The Kiplinger Letter We’re likely never going back to the historically low rates that prevailed in late 2019 and early 2020.
-
Rental Market Will Slow Through 2023: The Kiplinger Letter
The Kiplinger Letter Expected growth in the rental market is likely to remain slow for the rest of the year amid a slow housing market and cooling economy.
-
Passport Processing Times Speed Up: The Kiplinger Letter
The Kiplinger Letter The State Department credits an increase in staff and new technology with shrinking processing times.
